Singapore-based Quadria Capital to invest up to US$155 million in India’s Maxivision Eye Hospital
Add BT as a preferred source
SINGAPORE-BASED private equity firm Quadria Capital said on Wednesday (Jul 12) it will invest up to US$155 million in India’s Maxivision Eye Hospital.
Quadria, which focuses on healthcare investments around South and South-east Asia, said it will make an initial investment of about US$75 million for a minority stake and a further investment of up to US$80 million for additional equity.
Quadria did not provide a timeline for the investment.
The investment is to “support Maxivision’s ability to scale and serve the growing demand for eye care in India, particularly in Tier-2 and Tier-3 cities that remain underserved by the Indian eye care market,” the private equity firm said. Maxivision offers eye care services to over five million patients in 42 centres across six states in southern and western India.
Quadria Capital has previously invested in other Indian healthcare and pharmaceutical companies such as MediBuddy, Akums Drugs and Pharmaceuticals and Strand Life Sciences, according to their website. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
Private equity giant Carlyle can grow bigger but needs to stay on its toes: co-founder David Rubenstein
Singapore to establish over-the-counter gold clearing system, central bank vaulting by end-2026
Singapore public sector commands highest AI salary premium as job postings surge: PwC study
